Xaa$_2$ is an amino acid selected from the group consisting of Met, Thr, Cys and Ile and Xaa$_3$ is absent or between one and 7 amino acids.

2. (amended) The peptide ligand of claim 1 having the following formula:

   Xaa$_1$-Cys-Xaa$_2$-Gly-Pro-Gly-Cys-Xaa$_3$ (SEQ ID NO:92)

wherein Xaa$_1$ is absent or between one and fourteen amino acids; and Xaa$_2$ is an amino acid selected from the group consisting of Met, Ile, Thr or Cys and Xaa$_3$ is absent or between one and seven amino acids.

3. (amended) The peptide ligand of claim 2 having the following formula:

   Xaa$_1$-Cys-Ile-Gly-Pro-Gly-Cys-Xaa$_3$ (SEQ ID NO:161)

wherein Xaa$_1$ is absent or between one and seven amino acids.

5. (amended) The peptide ligand of claim 3 having the following formula:

   Xaa$_1$-Trp-Gly-Cys-Ile-Gly-Pro-Gly-Cys-Xaa$_3$ (SEQ ID NO:93)

wherein Xaa$_1$ is absent or between one and five amino acids.

6. (amended) The peptide ligand of claim 5 having the following formula:

   Xaa$_1$-Glu-Xaa$_4$-Trp-Gly-Cys-Ile-Gly-Pro-Gly-Cys-Xaa$_5$-Xaa$_6$-Leu-Xaa$_3$ (SEQ ID NO:87)

wherein Xaa$_1$ is absent or between one and three amino acids, Xaa$_4$ is an amino acid,

Xaa$_5$ is an amino acid,

Xaa$_6$ is an amino acid and

Xaa$_3$ is absent or between one and four amino acids.

09/609,721

7. (amended) The peptide ligand of claim 6 wherein Xaa is absent or selected from the group consisting of

Gln-Arg-Asn-

Leu-Ser-Pro-

Glu-Asn-Trp-

Ala-Ser-His-

Lys-Leu-Asn-

Thr-Gln-Ala-

Ala-Pro-Arg-

Gln-Val-Tyr-

Arg-Thr-Glu-

Phe-Ala-Gly-

Thr-Ala-Arg-

Arg-Pro-His-

Asn-Val-Cys-

Cys-Ile-Asp-

Tyr-Glu-Trp-

Arg-Trp-Asp-

His-Trp-Met-

Asn-Trp-Pro-

Phe-Asn-Trp-

Phe-Ser-Gly-

Gly-Gly-Trp-

Leu-Trp-Phe-

Gly-Ile-Pro-

Trp-Trp-Thr-

Leu-Gly-Trp-

Ser-Pro-Trp-

Arg-Gly-Trp-,

Xaa₄ is selected from the group consisting of:

Ala, Thr, Met, Val, Arg, Glu, Asp, Ser, Gln, Pro, Gly, Phe and Lys,

09/609,721

Xaa$_6$ is selected from the group consisting of:
Glu, Lys, Arg, Asp, Ser, Ala, Asn, Gly, Pro and Gln,
Xaa$_6$ is selected from the group consisting of:
Met, Phe, Ala, Met, Cys, Gln, Glu, Ala, Trp, Phe, Leu, Val, Tyr,
Trp, and

Xaa$_3$ is a four amino acid peptide having the following formula:
    -Xaa$_7$-Xaa$_8$-Cys-Xaa$_9$.

8.   (amended) The peptide ligand of claim 7 wherein -Xaa$_7$-Xaa$_8$-Cys-Xaa$_9$ is selected from the group consisting of:
-Gln-Ala-Cys-Met (SEQ ID NO:102)
-Leu-Gln-Cys-Trp (SEQ ID NO:103)
-Met-Ser-Cys-Val (SEQ ID NO:104)
-Leu-Arg-Cys-Ile (SEQ ID NO:105)
-Gln-Ala-Cys-Leu (SEQ ID NO:106)
-Leu-Ser-Cys-Leu (SEQ ID NO:107)
-Ile-Gly-Cys-Leu (SEQ ID NO:108)
-Leu-Ala-Cys-Leu (SEQ ID NO:109)
-Leu-Ser-Cys-Ile (SEQ ID NO:110)
-Met-Asn-Cys-Leu (SEQ ID NO:111)
-Leu-Arg-Cys-Leu (SEQ ID NO:112)
-Leu-Lys-Cys-Leu (SEQ ID NO:113)
-Leu-Gly-Cys-Leu (SEQ ID NO:114)
-Leu-Asn-Cys-Ile (SEQ ID NO:115)
-Met-Gly-Cys-Leu (SEQ ID NO:116) and
-Met-Ala-Cys-Leu (SEQ ID NO:117).

9.   (amended) The peptide ligand of claim 6 wherein Xaa$_3$ is a four amino acid peptide having the following formula
    -Cys-Xaa$_8$-Xaa$_{10}$-Cys
wherein Xaa$_8$ is an amino acid and Xaa$_{10}$ is an amino acid.

10. (amended) The peptide ligand of claim 9 wherein Xaa_1 is selected from the group consisting of:

-Cys-Ala-Trp-Cys (SEQ ID NO:118)

-Cys-Ser-Trp-Cys (SEQ ID NO:119)

-Cys-Glu-Pro-Cys (SEQ ID NO:120)

-Cys-Asp-Trp-Cys (SEQ ID NO:121)

-Cys-Glu-Trp-Cys (SEQ ID NO:122)

-Cys-Asn-Trp-Cys (SEQ ID NO:123) and

-Cys-Gly-Trp-Cys (SEQ ID NO:124).

21. (amended) A polypeptide which comprises:

(a) a peptide ligand having the following formula:

Xaa_1-Cys-Xaa_2-Gly-Pro-Gly-Cys-Xaa_3

wherein Xaa_1 is absent or between one and fourteen amino acids; and Xaa_2 is an amino acid selected from the group consisting of Met, Ile, Thr or Cys and Xaa_3 is absent or between one and seven amino acids and

(b) an immunoglobulin constant region sequence.

30. (amended) A pharmaceutical composition comprising a peptide ligand having the following formula:

Xaa_1-Cys-Xaa_2-Gly-Pro-Gly-Cys-Xaa_3

wherein Xaa_1 is absent or between one and fourteen amino acids; and Xaa_2 is an amino acid selected from the group consisting of Met, Ile, Thr or Cys and Xaa_3 is absent or between one and seven amino acids and pharmaceutically acceptable excipient.

Please add the following new claims:

39. (new) A composition comprising a peptide ligand having the following formula:

Xaa_1-Cys-Xaa_2-Gly-Pro-Gly-Cys-Xaa_3

wherein Xaa_1 is absent or between one and fourteen amino acids;